Dimensional Fund Advisors LP Has $830.49 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Dimensional Fund Advisors LP lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 1,689,790 shares of the medical research company’s stock after buying an additional 36,286 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Thermo Fisher Scientific were worth $830,486,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Assetmark Inc. lifted its holdings in Thermo Fisher Scientific by 22.9% during the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after purchasing an additional 7,023 shares during the last quarter. North Dakota State Investment Board bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $7,505,000. Northstar Advisory Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $3,250,000. Eagle Rock Investment Company LLC raised its stake in shares of Thermo Fisher Scientific by 15.9% in the fourth quarter. Eagle Rock Investment Company LLC now owns 21,969 shares of the medical research company’s stock valued at $12,730,000 after acquiring an additional 3,012 shares during the last quarter. Finally, Boston Trust Walden Corp boosted its holdings in shares of Thermo Fisher Scientific by 9.7% in the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock worth $25,480,000 after acquiring an additional 3,873 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Down 0.1%

Shares of TMO opened at $532.17 on Monday. The stock’s fifty day simple moving average is $484.57 and its 200-day simple moving average is $514.39. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $197.77 billion, a PE ratio of 29.26, a price-to-earnings-growth ratio of 2.36 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 12-month low of $403.36 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same period in the previous year, the business posted $5.15 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Piper Sandler started coverage on Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 price target for the company. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Stifel Nicolaus cut their price target on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a report on Friday, April 24th. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Finally, KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $602.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.